Paper38017349
Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
Darwish M and 3 others. Clin Drug Investig, 2024. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects. Papers, record 38017349. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38017349
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Liver | Major topic |
| Adult | |
| Humans | |
| Male | |
| Administration, Oral | |
| Chromatography, High Pressure Liquid | |
| Feces | |
| Glutamates |
Source PubMed
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6781809 | Determination of mean valproic acid serum level by assay of a single pooled sample. | Clin Pharmacol Ther | 1981 | https://conductscience.org/library/papers/6781809 | PubMed |
| 2 | 28522374 | Population pharmacokinetics of NNZ-2566 in healthy subjects. | Eur J Pharm Sci | 2017 | https://conductscience.org/library/papers/28522374 | PubMed |
| 3 | 37291210 | Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. | Nat Med | 2023 | https://conductscience.org/library/papers/37291210 | PubMed |
| 4 | 22013176 | Clinical severity and quality of life in children and adolescents with Rett syndrome. | Neurology | 2011 | https://conductscience.org/library/papers/22013176 | PubMed |
| 5 | 20516282 | Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers. | Antimicrob Agents Chemother | 2010 | https://conductscience.org/library/papers/20516282 | PubMed |
| 6 | 10508514 | Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. | Nat Genet | 1999 | https://conductscience.org/library/papers/10508514 | PubMed |
| 7 | 30918097 | Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. | Neurology | 2019 | https://conductscience.org/library/papers/30918097 | PubMed |
| 8 | 19157421 | NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke. | J Neurol Sci | 2009 | https://conductscience.org/library/papers/19157421 | PubMed |
| 9 | 28964591 | A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome. | Pediatr Neurol | 2017 | https://conductscience.org/library/papers/28964591 | PubMed |
| 10 | 30217666 | Behavioral profiles in Rett syndrome: Data from the natural history study. | Brain Dev | 2019 | https://conductscience.org/library/papers/30217666 | PubMed |
| 11 | 28750160 | Two Phase 1, Open-Label, Mass Balance Studies to Determine the Pharmacokinetics of 14 C-Labeled Isavuconazonium Sulfate in Healthy Male Volunteers. | Clin Pharmacol Drug Dev | 2018 | https://conductscience.org/library/papers/28750160 | PubMed |
| 12 | 22331013 | Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. | J Pediatr Gastroenterol Nutr | 2012 | https://conductscience.org/library/papers/22331013 | PubMed |
| 13 | 19208815 | Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. | Proc Natl Acad Sci U S A | 2009 | https://conductscience.org/library/papers/19208815 | PubMed |
| 14 | 30973970 | Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor. | Br J Clin Pharmacol | 2019 | https://conductscience.org/library/papers/30973970 | PubMed |
| 15 | 35622206 | A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects. | Clin Drug Investig | 2022 | https://conductscience.org/library/papers/35622206 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42377739 | Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide. | Adv Ther | 2026 | https://conductscience.org/library/papers/42377739 | PubMed |
| 41678137 | A Phase 1, Randomized, Open-Label Study to Assess the Bioequivalence of Trofinetide as a Ready-to-Use Oral Solution and Constituted Powder for Oral Solution in Healthy Adults. | Adv Ther | 2026 | https://conductscience.org/library/papers/41678137 | PubMed |
| 39692837 | Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome. | Adv Ther | 2025 | https://conductscience.org/library/papers/39692837 | PubMed |
| 39692836 | Population Pharmacokinetic Modeling to Support Trofinetide Dosing for the Treatment of Rett Syndrome. | Adv Ther | 2025 | https://conductscience.org/library/papers/39692836 | PubMed |
| 39516357 | Physiologically-Based Pharmacokinetic Modeling of Trofinetide in Moderate Renal Impairment for Phase 1 Clinical Study Dose Selection with Model Validation. | Eur J Drug Metab Pharmacokinet | 2025 | https://conductscience.org/library/papers/39516357 | PubMed |
| 38963587 | Effect of Hepatic Impairment on Trofinetide Exposures Using an In Silico Physiologically Based Pharmacokinetic Model. | Adv Ther | 2024 | https://conductscience.org/library/papers/38963587 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38017349
GET https://conductscience.org/api/papers/v1/38017349/authors